Fagron NV 4A5.F Stock
Fagron NV Price Chart
Fagron NV 4A5.F Financial and Trading Overview
| Fagron NV stock price | 17.7 EUR |
| Previous Close | 15.9 EUR |
| Open | 15.73 EUR |
| Bid | 15.79 EUR x 145000 |
| Ask | 15.82 EUR x 145000 |
| Day's Range | 15.73 - 15.73 EUR |
| 52 Week Range | 10.98 - 17.64 EUR |
| Volume | 74 EUR |
| Avg. Volume | 2 EUR |
| Market Cap | 1.15B EUR |
| Beta (5Y Monthly) | 0.440229 |
| PE Ratio (TTM) | 16.216494 |
| EPS (TTM) | 0.97 EUR |
| Forward Dividend & Yield | 0.25 (1.55%) |
| Ex-Dividend Date | May 15, 2023 |
| 1y Target Est | N/A |
4A5.F Valuation Measures
| Enterprise Value | 1.45B EUR |
| Trailing P/E | 16.216494 |
| Forward P/E | N/A |
| PEG Ratio (5 yr expected) | N/A |
| Price/Sales (ttm) | 1.681963 |
| Price/Book (mrq) | 2.834234 |
| Enterprise Value/Revenue | 2.12 |
| Enterprise Value/EBITDA | 13.447 |
Trading Information
Fagron NV Stock Price History
| Beta (5Y Monthly) | 0.440229 |
| 52-Week Change | 1.26% |
| S&P500 52-Week Change | 20.43% |
| 52 Week High | 17.64 EUR |
| 52 Week Low | 10.98 EUR |
| 50-Day Moving Average | 16.64 EUR |
| 200-Day Moving Average | 14.08 EUR |
4A5.F Share Statistics
| Avg. Volume (3 month) | 2 EUR |
| Avg. Daily Volume (10-Days) | 7 EUR |
| Shares Outstanding | 73.13M |
| Float | 66.42M |
| Short Ratio | N/A |
| % Held by Insiders | 5.14% |
| % Held by Institutions | 83.41% |
| Shares Short | N/A |
| Short % of Float | N/A |
| Short % of Shares Outstanding | N/A |
Dividends & Splits
| Trailing Annual Dividend Rate | 0.25 |
| Trailing Annual Dividend Yield | 1.57% |
| 5 Year Average Dividend Yield | 87.00% |
| Payout Ratio | 0.2083 |
| Last Split Factor |
Financial Highlights
Fiscal Year
| Fiscal Year Ends | December 31, 2022 |
| Most Recent Quarter (mrq) | December 31, 2022 |
| Next Fiscal Year End | December 31, 2023 |
Profitability
| Profit Margin | 10.17% |
| Operating Margin (ttm) | 13.38% |
| Gross Margin | 41.84% |
| EBITDA Margin | 15.76% |
Management Effectiveness
| Return on Assets (ttm) | 6.45% |
| Return on Equity (ttm) | 19.04% |
Income Statement
| Revenue (ttm) | 683.88M EUR |
| Revenue Per Share (ttm) | 9.38 EUR |
| Quarterly Revenue Growth (yoy) | 19.50% |
| Gross Profit (ttm) | 286.16M EUR |
| EBITDA | 107.83M EUR |
| Net Income Avi to Common (ttm) | 69.61M EUR |
| Diluted EPS (ttm) | 0.97 |
| Quarterly Earnings Growth (yoy) | 0.59% |
Balance Sheet
| Total Cash (mrq) | 125.34M EUR |
| Total Cash Per Share (mrq) | 1.72 EUR |
| Total Debt (mrq) | 399.56M EUR |
| Total Debt/Equity (mrq) | 97.33 EUR |
| Current Ratio (mrq) | 1.86 |
| Book Value Per Share (mrq) | 5.55 |
Cash Flow Statement
| Operating Cash Flow (ttm) | 109.46M EUR |
| Levered Free Cash Flow (ttm) | 56.73M EUR |
Profile of Fagron NV
| Country | Germany |
| State | N/A |
| City | Nazareth |
| Address | Venecoweg 20A |
| ZIP | 9810 |
| Phone | 32 8 001 28 80 |
| Website | https://www.fagron.com |
| Industry | Drug Manufacturers-Specialty & Generic |
| Sector(s) | Healthcare |
| Full Time Employees | 3035 |
Fagron NV, a pharmaceutical compounding company, delivers personalized pharmaceutical care to hospitals, pharmacies, clinics, and patients worldwide. It operates in three segments: Essentials, Brands, and Compounding Services. The company also innovates concepts, vehicles, and formulations for pharmaceutical compounding. Its products include DiluCap, a line of excipients to compound every capsule formulation; Imuno TF Complex helps in regulation of immune responses; Pigmerise, a natural phytocomplex for hypopigmentation disorders; Pentravan uses for avoiding first-pass metabolism and preventing gastrointestinal erosion; Nourisil MD, a first line therapy for prevention and treatment of scars ang keloids; Neogen, a line of hair care products; TrichoConcept used to treat alopecia; Fagron Advanced Derma for basic skincare, compound pharmaceutical treatment, and individualized dermatological care; and SyrSpend SF that provides pharmaceutical stability, dosage consistency, and patient comfort. In addition, the company offers education and training program to prescribers and pharmacists through the Fagron Academy. The company was formerly known as Arseus NV and changed its name to Fagron NV in January 2015. Fagron NV was founded in 1990 and is based in Nazareth, Belgium.
Q&A For Fagron NV Stock
What is a current 4A5.F stock price?
Fagron NV 4A5.F stock price today per share is 17.7 EUR.
How to purchase Fagron NV stock?
You can buy 4A5.F shares on the Frankfurt exchange. Contact your financial advisor to select a broker.
What is the ticker symbol for Fagron NV?
The stock symbol or ticker of Fagron NV is 4A5.F.
Which industry does the Fagron NV company belong to?
The Fagron NV industry is Drug Manufacturers-Specialty & Generic.
How many shares does Fagron NV have in circulation?
The max supply of Fagron NV shares is 72.99M.
What is Fagron NV Price to Earnings Ratio (PE Ratio)?
Fagron NV PE Ratio is 18.24742300 now.
What was Fagron NV earnings per share over the trailing 12 months (TTM)?
Fagron NV EPS is 0.97 EUR over the trailing 12 months.
Which sector does the Fagron NV company belong to?
The Fagron NV sector is Healthcare.